
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a report published in the Health Services Research that examined how Washington state reduced the number of antipsychotic prescriptions written for children in the Medicaid system.
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a report published in the Health Services Research that examined how Washington state reduced the number of antipsychotic prescriptions written for children in the Medicaid system.






